Based on the benefits achieved for the treatment of other malignancies, CD47-targeting antibody and human (or murine) SIRPα-Fc have been used to access the anti-tumor effect of GBM by blocking CD47-SIRPα axis in vitro and in vivo. The gene discussed is CD47; the disease is glioblastoma.